来自接受青蒿琥酯-咯萘啶治疗的苏丹疟疾病人的疟原虫 Pfmdr1 拷贝数增加和序列多态性。
Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine.
机构信息
Department of Epidemiology, Tropical Medicine Research Institute, National Centre for Research, Khartoum, Sudan.
出版信息
Antimicrob Agents Chemother. 2011 Nov;55(11):5408-11. doi: 10.1128/AAC.05102-11. Epub 2011 Sep 6.
Abstract
Molecular markers for surveillance of Plasmodium falciparum resistance to current antimalarials are sorely needed. A 28-day efficacy study of artemether-lumefantrine in eastern Sudan identified 5 treatment failures among 100 evaluable patients; 9 further individuals were parasite positive by PCR during follow-up. Polymorphisms in pfatpase6 and pfmdr1 were evaluated by DNA sequencing. One individual carried parasites with a novel pfmdr1 polymorphism (F1044L). pfmdr1 gene amplification in parasites prior to treatment occurred in three individuals who had recurrent infection during follow-up.
摘要
迫切需要用于监测恶性疟原虫对现有抗疟药物耐药性的分子标志物。在苏丹东部进行的为期 28 天的青蒿琥酯-咯萘啶疗效研究中，在 100 例可评估的患者中发现 5 例治疗失败；9 例进一步的个体在随访期间通过 PCR 检测到寄生虫阳性。通过 DNA 测序评估 pfATPase6 和 pfmdr1 的多态性。一名个体携带具有新型 pfmdr1 多态性（F1044L）的寄生虫。在治疗前，有 3 例个体的 pfmdr1 基因在寄生虫中扩增，他们在随访期间出现了复发性感染。
相似文献
1
Increased pfmdr1 copy number and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients treated with artemether-lumefantrine.来自接受青蒿琥酯-咯萘啶治疗的苏丹疟疾病人的疟原虫 Pfmdr1 拷贝数增加和序列多态性。
Antimicrob Agents Chemother. 2011 Nov;55(11):5408-11. doi: 10.1128/AAC.05102-11. Epub 2011 Sep 6.
2
Selection of Plasmodium falciparum pfcrt and pfmdr1 polymorphisms after treatment with artesunate-amodiaquine fixed dose combination or artemether-lumefantrine in Liberia.在利比里亚，用青蒿琥酯-阿莫地喹固定剂量复方或蒿甲醚-本芴醇治疗后恶性疟原虫pfcrt和pfmdr1基因多态性的选择
Malar J. 2016 Sep 5;15(1):452. doi: 10.1186/s12936-016-1503-3.
3
Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia.柬埔寨恶性疟原虫中Pfmdr1基因拷贝数与青蒿素衍生物联合疗法失败情况
Malar J. 2009 Jan 12;8:11. doi: 10.1186/1475-2875-8-11.
4
Evaluation of artemether-lumefantrine efficacy in the treatment of uncomplicated malaria and its association with pfmdr1, pfatpase6 and K13-propeller polymorphisms in Luanda, Angola.在安哥拉罗安达评估蒿甲醚-本芴醇治疗非复杂性疟疾的疗效及其与pfmdr1、pfatpase6和K13-螺旋桨基因多态性的关联。
Malar J. 2015 Dec 16;14:504. doi: 10.1186/s12936-015-1018-3.
5
K13 mutations and pfmdr1 copy number variation in Plasmodium falciparum malaria in Myanmar.缅甸恶性疟原虫疟疾中K13突变和pfmdr1拷贝数变异
Malar J. 2016 Feb 24;15:110. doi: 10.1186/s12936-016-1147-3.
6
Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria.蒿甲醚-本芴醇对尼日利亚单纯性恶性疟患儿无性期和配子体中恶性疟原虫多药耐药基因1等位基因的选择作用
Antimicrob Agents Chemother. 2009 Mar;53(3):888-95. doi: 10.1128/AAC.00968-08. Epub 2008 Dec 15.
7
Baseline in vivo, ex vivo and molecular responses of Plasmodium falciparum to artemether and lumefantrine in three endemic zones for malaria in Colombia.哥伦比亚三个疟疾流行区恶性疟原虫对蒿甲醚和本芴醇的基线体内、体外及分子反应
Trans R Soc Trop Med Hyg. 2017 Feb 1;111(2):71-80. doi: 10.1093/trstmh/trx021.
8
Increased prevalence of the Plasmodium falciparum Pfmdr1 86N genotype among field isolates from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and artesunate-mefloquine.在法国城市加蓬的班古替换氯喹为青蒿琥酯-咯萘啶和青蒿琥酯-甲氟喹后，恶性疟原虫 Pfmdr1 86N 基因型的流行率增加。
Infect Genet Evol. 2011 Mar;11(2):512-7. doi: 10.1016/j.meegid.2011.01.003. Epub 2011 Jan 17.
9
Selection of N86F184D1246 haplotype of Pfmrd1 gene by artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal.蒿甲醚-本芴醇药物压力对塞内加尔恶性疟原虫群体中Pfmrd1基因N86F184D1246单倍型的选择作用
Malar J. 2016 Aug 25;15(1):433. doi: 10.1186/s12936-016-1490-4.
10
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.在布基纳法索，青蒿琥酯-咯萘啶和阿莫地喹-磺胺多辛-乙胺嘧啶选择已知的疟原虫耐药相关多态性，但二氢青蒿素-哌喹没有。
Antimicrob Agents Chemother. 2010 May;54(5):1949-54. doi: 10.1128/AAC.01413-09. Epub 2010 Mar 15.
引用本文的文献
1
Plasmodium falciparum multidrug resistance 1 gene polymorphisms associated with outcomes after anti-malarial treatment.恶性疟原虫多药耐药1基因多态性与抗疟治疗后的结局相关。
Malar J. 2025 Jun 12;24(1):186. doi: 10.1186/s12936-025-05248-2.
2
Identification of a large anion channel required for digestive vacuole acidification and amino acid export in Plasmodium falciparum.恶性疟原虫消化泡酸化和氨基酸输出所需的一种大型阴离子通道的鉴定。
PLoS Biol. 2025 May 30;23(5):e3003202. doi: 10.1371/journal.pbio.3003202. eCollection 2025 May.
3
Artemether-Lumefantrine Treatment Selects Plasmodium falciparum Multidrug Resistance 1 (pfmdr1) Increased Copy Number Among African Malaria Infections.蒿甲醚-本芴醇治疗在非洲疟疾感染中选择了恶性疟原虫多药耐药性1（pfmdr1）拷贝数增加的情况。
J Infect Dis. 2025 Jul 11;231(6):e1119-e1128. doi: 10.1093/infdis/jiaf155.
4
Low prevalence of copy number variation in pfmdr1 and pfpm2 in Plasmodium falciparum isolates from southern Angola.安哥拉南部恶性疟原虫分离株中pfmdr1和pfpm2基因拷贝数变异的低流行率
Malar J. 2025 Jan 10;24(1):5. doi: 10.1186/s12936-024-05240-2.
5
Increased sensitivity of malaria parasites to common antimalaria drugs after the introduction of artemether-lumefantrine: Implication of policy change and implementation of more effective drugs in fight against malaria.青蒿琥酯-咯萘啶引入后疟原虫对常见抗疟药物敏感性增加：政策改变和更有效的药物实施对疟疾防治的影响。
PLoS One. 2024 Jun 20;19(6):e0298585. doi: 10.1371/journal.pone.0298585. eCollection 2024.
6
Treatment Failure in a UK Malaria Patient Harboring Genetically Variant Plasmodium falciparum From Uganda With Reduced In Vitro Susceptibility to Artemisinin and Lumefantrine.英国疟疾病例治疗失败，携带源自乌干达具遗传变异的疟原虫 falciparum，对青蒿素和咯萘啶的体外敏感性降低。
Clin Infect Dis. 2024 Feb 17;78(2):445-452. doi: 10.1093/cid/ciad724.
7
The structure of multidrug resistance protein 1 reveals an N-terminal regulatory domain.多药耐药蛋白 1 的结构揭示了一个 N 端调节结构域。
Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2219905120. doi: 10.1073/pnas.2219905120. Epub 2023 Aug 1.
8
Clinical isolates of uncomplicated falciparum malaria from high and low malaria transmission areas show distinct pfcrt and pfmdr1 polymorphisms in western Ethiopia.来自高、低疟疾传播地区的无并发症恶性疟原虫临床分离株在埃塞俄比亚西部显示出明显的 pfcrt 和 pfmdr1 多态性。
Malar J. 2023 Jun 3;22(1):171. doi: 10.1186/s12936-023-04602-6.
9
Seasonal Malaria Chemoprevention Implementation: Effect on Malaria Incidence and Immunity in a Context of Expansion of Resistant Genotypes with Potential Reduction of the Effectiveness in Sub-Saharan Africa.季节性疟疾化学预防的实施：在撒哈拉以南非洲耐药基因型扩大且有效性可能降低的背景下对疟疾发病率和免疫力的影响
Infect Drug Resist. 2022 Aug 13;15:4517-4527. doi: 10.2147/IDR.S375197. eCollection 2022.
10
Mapping partner drug resistance to guide antimalarial combination therapy policies in sub-Saharan Africa.绘制伙伴药物耐药性图谱以指导撒哈拉以南非洲的抗疟联合治疗政策。
Proc Natl Acad Sci U S A. 2021 Jul 20;118(29). doi: 10.1073/pnas.2100685118.
本文引用的文献
1
Self-reported fever, treatment actions and malaria infection prevalence in the northern states of Sudan.苏丹北部各州的自我报告发热、治疗措施和疟疾感染流行情况。
Malar J. 2011 May 15;10:128. doi: 10.1186/1475-2875-10-128.
2
pfmdr1 amplification associated with clinical resistance to mefloquine in West Africa: implications for efficacy of artemisinin combination therapies.pfmdr1 扩增与西非地区对甲氟喹的临床耐药性相关：对青蒿素联合疗法疗效的影响。
J Clin Microbiol. 2010 Oct;48(10):3797-9. doi: 10.1128/JCM.01057-10. Epub 2010 Jul 28.
3
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.对恶性疟原虫 SERCA（PfATP6）L263E 突变在青蒿素作用和耐药性中的作用的研究。
Antimicrob Agents Chemother. 2010 Sep;54(9):3842-52. doi: 10.1128/AAC.00121-10. Epub 2010 Jun 21.
4
Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum.探讨候选基因对恶性疟原虫青蒿素耐药性的贡献。
Antimicrob Agents Chemother. 2010 Jul;54(7):2886-92. doi: 10.1128/AAC.00032-10. Epub 2010 Apr 26.
5
Multiple genetic backgrounds of the amplified Plasmodium falciparum multidrug resistance (pfmdr1) gene and selective sweep of 184F mutation in Cambodia.柬埔寨恶性疟原虫多药耐药基因（pfmdr1）扩增的多种遗传背景和 184F 突变的选择清除。
J Infect Dis. 2010 May 15;201(10):1551-60. doi: 10.1086/651949.
6
Markers of anti-malarial drug resistance in Plasmodium falciparum isolates from Swaziland: identification of pfmdr1-86F in natural parasite isolates.斯威士兰疟原虫分离株中的抗疟药物耐药标志物：天然寄生虫分离株中 pfmdr1-86F 的鉴定。
Malar J. 2010 Mar 3;9:68. doi: 10.1186/1475-2875-9-68.
7
Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity.恶性疟原虫肌浆（内）质网 Ca2+-ATP 酶（PfSERCA）基因多样性的地理结构。
PLoS One. 2010 Feb 25;5(2):e9424. doi: 10.1371/journal.pone.0009424.
8
Descriptive study on the efficacy of artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Sudan.描述性研究：青蒿琥酯-咯萘啶治疗苏丹无并发症恶性疟的疗效。
Eur J Clin Pharmacol. 2010 Mar;66(3):231-7. doi: 10.1007/s00228-009-0750-4.
9
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
10
Evidence of artemisinin-resistant malaria in western Cambodia.柬埔寨西部出现青蒿素耐药性疟疾的证据。
N Engl J Med. 2008 Dec 11;359(24):2619-20. doi: 10.1056/NEJMc0805011. Epub 2008 Dec 8.
Zotero 插件